Proactive Investors
14 Jul 2026, 17:37 UTC · 1h ago
Moderna set for uneventful Q2 report ahead of key data readouts, says Jefferies
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
14 Jul 2026, 17:37 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Moderna is expecting Phase III data for its personalized cancer vaccine candidate (mRNA-4157) in the second half of 2026. — Positive Phase III results for a major oncology candidate are a primary catalyst for stock valuation and a shift in the company's growth profile beyond COVID-19.
+0.80Moderna's mFluSiva flu vaccine candidate is expected to receive US regulatory approval by August 5, 2026. — Regulatory approval expands the product portfolio and validates the mRNA platform, though commercial impact is delayed until 2027.
+0.50Moderna's second-quarter revenue is projected at $50 million to $100 million, a significant drop from $389 million in Q1. — While expected due to seasonality, the sharp quarterly revenue decline highlights the company's current dependence on seasonal COVID vaccine cycles.
-0.30Continue reading
6 related stories
Top 3 movers · tap to explore
Jefferies forecasts a loss of $1.99 per share for the second quarter, slightly worse than the consensus expectation of $1.97. — A slight earnings miss is generally a minor negative, though it reinforces the current loss-making phase of the business.
-0.10Which stocks this story touches
Despite seasonal revenue declines, the company has strong YTD outperformance and several high-potential pipeline catalysts in oncology and flu vaccines.
Mentioned positively in the context of a collaborative personalized cancer vaccine trial.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
24/7 Wall Street
3h ago
